Table 3.
Clinical follow‐up of adoptive T‐cell therapy of patients with recurrent GBM
| Number of cells per infusion | Number of infusions | Time to progression after first infusion (months) | Treatment in addition to T cells | Follow‐up since first infusion (months) | Current status | |
|---|---|---|---|---|---|---|
| 1 | 3 × 107 | 4 | TMZ | 108.7 | Alive | |
| 2 | 2.8 × 107 | 4 | 1.9 | Avastin | 10.8 | Deceased |
| 3 | 2.0 × 107 | 3 | 4.4 | TMZ, avastin, thalidomide | 81.2 | Deceased |
| 4 | 2.9 × 107 | 4 | TMZ | 33.2 | Deceased[Link] | |
| 6 | 4 × 107 | 4 | 1.2 | Avastin, TMZ | 5.0 | Deceased |
| 7 | 3.5 × 107 | 2 | 0.7 | TMZ | 1.1 | Deceased |
| 9 | 2.5 × 107 | 4 | 68.5 | TMZ | 76.3 | Alive |
| 13 | 3.2 × 107 | 4 | 1.1 | Avastin, CCNU | 3.3 | Deceased |
| 15 | 2.5 × 107 | 3 | 9.4 | 10.4 | Deceased | |
| 16 | 4 × 107 | 4 | 4.7 | TMZ, surgery | 15.1 | Deceased |
| 19 | 3 × 107 | 3 | 7.7 | Avastin, CCNU | 10.6 | Deceased |
| 22 | 3 × 107 | 4 | 6.9 | Avastin | 8.6 | Deceased |
Cause of death not related to GBM.